All Solid Tumors
Cancer Type
Tumor Tissue (FFPE)
Specimen Requirements
7 Working Days
Turnaround Time ¹
ACTDrug®+ is an NGS‑based test that profiles 101 genes to detect clinically relevant gene alterations aligned with FDA‑approved and NCCN guideline‑recommended targeted therapies, supporting timely treatment decisions.
Hallmarks
101 genes
Assesses clinically relevant gene alterations aligned with FDA-approved and NCCN guideline-recommended targetedtherapies, supporting informed first-line treatment decisions
Whole Coding-Region Design
Comprehensive variant detection and identification of clinically actionable alterations.
Resistance Mutation Insight
Provides genomic insights into variants associated with treatment resistance.
RNA-based NGS Fusion Detection
Enables assessment of known and novel gene fusion events, supporting identification of patients who may benefit from targetedtherapy.
7 Working Days
Rapid turnaround time.
Summary
Actionable Insights of Biomarkers for Your Cancer Patient
Provides genomic profiling for clinically actionable genes.
Timely Treatment Options Through Cancer Genomic Profiling
ACTDrug®+ is a next-generation sequencing (NGS)-based assay, which sequences 101 actionable genes from cancer specimens in our CAP-accredited laboratory. This assay is designed for patients across multiple cancer types such as breast, lung, colorectalgastric cancers…etc, providing tailored genomic profiling and recommendations of targeted drugs.
Explore Various Genetic Alterations for More TherapeuticImplication
ACTDrug®+ performs various genetic variation analyses. In addition to single-nucleotide variation (SNV) and small insertion/ deletion (InDel), the assay detects copy number variations(CNVs), large genomic rearrangements in BRCA1 and BRCA2, gene fusions, and microsatellite instability (MSI), providing clinically relevant alterations.
For All Solid Tumors
Selects the most suitable treatment for newly diagnosed advanced and/ or metastatic patients based on actionable genetic mutations.
Easy-to-Interpret Medical Report
Actionable summary of the detected variant and associated therapies. Variant reporting and classification are based on levels of evidence, prioritizing treatment-related evidence supported by international publications and guidelines.
Technical Specifications
Next Generation Sequencing (NGS)
101 actionable genes
Specimen Requirements2
FFPE Tumor Tissue
5-20 unstained sections (5 μm/slide, surface area ≥ 125 mm2)
1 H&E-stained slide (5 μm)
Sequencing Mean Depth
≥ 600 x
Sensitivity3
SNVand Indels: 100%, CNAs: 95%, LGR (BRCA1/2): 100%, Fusion 100%, MSI: 100%
Specificity3
SNVand Indels: 100%, CNAs: 100%, LGR (BRCA1/2): 94%, Fusion 100%, MSI: 94%
Documentation
Gene List
Disclaimers / Footnotes
- Turnaround time starts from the date of receipt of qualified samples at our CAP-accredited laboratory.
- Please refer to our specimen instructions.
- Analytical performance was established under defined validation conditions
